Predictors of progression in patients with Friedreich ataxia
Identifieur interne : 001845 ( Istex/Corpus ); précédent : 001844; suivant : 001846Predictors of progression in patients with Friedreich ataxia
Auteurs : Alison La Pean ; Neal Jeffries ; Chelsea Grow ; Bernard Ravina ; Nicholas A. Di ProsperoSource :
- Movement Disorders [ 0885-3185 ] ; 2008-10-30.
English descriptors
- KwdEn :
Abstract
Friedreich ataxia is an inherited, progressive, neurodegenerative disorder that is clinically heterogeneous. It is caused by a trinucleotide (GAA) repeat expansion resulting in frataxin loss and oxidative stress. We assessed clinical features including the development of cardiomyopathy and scoliosis and disease progression including loss of ambulation and interference with activities of daily living relative to the length of the GAA repeat, age of onset, and age of diagnosis in a retrospective cohort study of 61 genetically confirmed patients. The use of antioxidants such as vitamins, dietary supplements, and idebenone was also examined. Linear regression and Cox proportional hazard models assessed predictors to disease milestones. The shorter GAA allele accounted for part of the variability in the age of diagnosis (46%) and less in the age of onset (27%). Multivariate analysis demonstrated that age at diagnosis, which may incorporate other genetic and environmental factors, is more important than GAA length in predicting cardiomyopathy, scoliosis, and disease progression. © 2008 Movement Disorder Society
Url:
DOI: 10.1002/mds.22248
Links to Exploration step
ISTEX:4114A5D3C6DC7EF365712917777C0686C790C098Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Predictors of progression in patients with Friedreich ataxia</title><author><name sortKey="La Pean, Alison" sort="La Pean, Alison" uniqKey="La Pean A" first="Alison" last="La Pean">Alison La Pean</name><affiliation><mods:affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Jeffries, Neal" sort="Jeffries, Neal" uniqKey="Jeffries N" first="Neal" last="Jeffries">Neal Jeffries</name><affiliation><mods:affiliation>Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Grow, Chelsea" sort="Grow, Chelsea" uniqKey="Grow C" first="Chelsea" last="Grow">Chelsea Grow</name><affiliation><mods:affiliation>Memorial Neurosciences, Gulfport, Mississippi, USA</mods:affiliation></affiliation></author><author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Di Prospero, Nicholas A" sort="Di Prospero, Nicholas A" uniqKey="Di Prospero N" first="Nicholas A." last="Di Prospero">Nicholas A. Di Prospero</name><affiliation><mods:affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4114A5D3C6DC7EF365712917777C0686C790C098</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/mds.22248</idno><idno type="url">https://api.istex.fr/document/4114A5D3C6DC7EF365712917777C0686C790C098/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001845</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Predictors of progression in patients with Friedreich ataxia</title><author><name sortKey="La Pean, Alison" sort="La Pean, Alison" uniqKey="La Pean A" first="Alison" last="La Pean">Alison La Pean</name><affiliation><mods:affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Jeffries, Neal" sort="Jeffries, Neal" uniqKey="Jeffries N" first="Neal" last="Jeffries">Neal Jeffries</name><affiliation><mods:affiliation>Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</mods:affiliation></affiliation></author><author><name sortKey="Grow, Chelsea" sort="Grow, Chelsea" uniqKey="Grow C" first="Chelsea" last="Grow">Chelsea Grow</name><affiliation><mods:affiliation>Memorial Neurosciences, Gulfport, Mississippi, USA</mods:affiliation></affiliation></author><author><name sortKey="Ravina, Bernard" sort="Ravina, Bernard" uniqKey="Ravina B" first="Bernard" last="Ravina">Bernard Ravina</name><affiliation><mods:affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</mods:affiliation></affiliation></author><author><name sortKey="Di Prospero, Nicholas A" sort="Di Prospero, Nicholas A" uniqKey="Di Prospero N" first="Nicholas A." last="Di Prospero">Nicholas A. Di Prospero</name><affiliation><mods:affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-10-30">2008-10-30</date><biblScope unit="vol">23</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2026">2026</biblScope><biblScope unit="page" to="2032">2032</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">4114A5D3C6DC7EF365712917777C0686C790C098</idno><idno type="DOI">10.1002/mds.22248</idno><idno type="ArticleID">MDS22248</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Friedreich ataxia</term><term>GAA expansion</term><term>genotype</term><term>medication</term><term>phenotype</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Friedreich ataxia is an inherited, progressive, neurodegenerative disorder that is clinically heterogeneous. It is caused by a trinucleotide (GAA) repeat expansion resulting in frataxin loss and oxidative stress. We assessed clinical features including the development of cardiomyopathy and scoliosis and disease progression including loss of ambulation and interference with activities of daily living relative to the length of the GAA repeat, age of onset, and age of diagnosis in a retrospective cohort study of 61 genetically confirmed patients. The use of antioxidants such as vitamins, dietary supplements, and idebenone was also examined. Linear regression and Cox proportional hazard models assessed predictors to disease milestones. The shorter GAA allele accounted for part of the variability in the age of diagnosis (46%) and less in the age of onset (27%). Multivariate analysis demonstrated that age at diagnosis, which may incorporate other genetic and environmental factors, is more important than GAA length in predicting cardiomyopathy, scoliosis, and disease progression. © 2008 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Alison La Pean MS, CGC</name><affiliations><json:string>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</json:string></affiliations></json:item><json:item><name>Neal Jeffries PhD</name><affiliations><json:string>Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</json:string></affiliations></json:item><json:item><name>Chelsea Grow DO</name><affiliations><json:string>Memorial Neurosciences, Gulfport, Mississippi, USA</json:string></affiliations></json:item><json:item><name>Bernard Ravina MD, MSCE</name><affiliations><json:string>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</json:string></affiliations></json:item><json:item><name>Nicholas A. Di Prospero MD, PhD</name><affiliations><json:string>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Friedreich ataxia</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>genotype</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>phenotype</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>GAA expansion</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>medication</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Friedreich ataxia is an inherited, progressive, neurodegenerative disorder that is clinically heterogeneous. It is caused by a trinucleotide (GAA) repeat expansion resulting in frataxin loss and oxidative stress. We assessed clinical features including the development of cardiomyopathy and scoliosis and disease progression including loss of ambulation and interference with activities of daily living relative to the length of the GAA repeat, age of onset, and age of diagnosis in a retrospective cohort study of 61 genetically confirmed patients. The use of antioxidants such as vitamins, dietary supplements, and idebenone was also examined. Linear regression and Cox proportional hazard models assessed predictors to disease milestones. The shorter GAA allele accounted for part of the variability in the age of diagnosis (46%) and less in the age of onset (27%). Multivariate analysis demonstrated that age at diagnosis, which may incorporate other genetic and environmental factors, is more important than GAA length in predicting cardiomyopathy, scoliosis, and disease progression. © 2008 Movement Disorder Society</abstract><qualityIndicators><score>5.955</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1122</abstractCharCount><pdfWordCount>4023</pdfWordCount><pdfCharCount>25773</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>161</abstractWordCount></qualityIndicators><title>Predictors of progression in patients with Friedreich ataxia</title><genre><json:string>Serial article</json:string></genre><host><volume>23</volume><pages><total>7</total><last>2032</last><first>2026</first></pages><issn><json:string>0885-3185</json:string></issn><issue>14</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2008</publicationDate><copyrightDate>2008</copyrightDate><doi><json:string>10.1002/mds.22248</json:string></doi><id>4114A5D3C6DC7EF365712917777C0686C790C098</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/4114A5D3C6DC7EF365712917777C0686C790C098/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/4114A5D3C6DC7EF365712917777C0686C790C098/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/4114A5D3C6DC7EF365712917777C0686C790C098/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Predictors of progression in patients with Friedreich ataxia</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2008</date></publicationStmt><notesStmt><note type="content">*Potential conflict of interest: None reported.</note><note>National Institute of Neurological Disorders and Stroke</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Predictors of progression in patients with Friedreich ataxia</title><author><persName><forename type="first">Alison</forename><surname>La Pean</surname><roleName type="degree">MS, CGC</roleName></persName><note type="correspondence"><p>Correspondence: Neurogenetics Branch, NINDS, 35 Convent Drive, Building 35, Room 2A‐114, Bethesda, MD 20892‐3705</p></note><affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</affiliation></author><author><persName><forename type="first">Neal</forename><surname>Jeffries</surname><roleName type="degree">PhD</roleName></persName><affiliation>Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</affiliation></author><author><persName><forename type="first">Chelsea</forename><surname>Grow</surname><roleName type="degree">DO</roleName></persName><affiliation>Memorial Neurosciences, Gulfport, Mississippi, USA</affiliation></author><author><persName><forename type="first">Bernard</forename><surname>Ravina</surname><roleName type="degree">MD, MSCE</roleName></persName><affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</affiliation></author><author><persName><forename type="first">Nicholas A.</forename><surname>Di Prospero</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-10-30"></date><biblScope unit="vol">23</biblScope><biblScope unit="issue">14</biblScope><biblScope unit="page" from="2026">2026</biblScope><biblScope unit="page" to="2032">2032</biblScope></imprint></monogr><idno type="istex">4114A5D3C6DC7EF365712917777C0686C790C098</idno><idno type="DOI">10.1002/mds.22248</idno><idno type="ArticleID">MDS22248</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2008</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Friedreich ataxia is an inherited, progressive, neurodegenerative disorder that is clinically heterogeneous. It is caused by a trinucleotide (GAA) repeat expansion resulting in frataxin loss and oxidative stress. We assessed clinical features including the development of cardiomyopathy and scoliosis and disease progression including loss of ambulation and interference with activities of daily living relative to the length of the GAA repeat, age of onset, and age of diagnosis in a retrospective cohort study of 61 genetically confirmed patients. The use of antioxidants such as vitamins, dietary supplements, and idebenone was also examined. Linear regression and Cox proportional hazard models assessed predictors to disease milestones. The shorter GAA allele accounted for part of the variability in the age of diagnosis (46%) and less in the age of onset (27%). Multivariate analysis demonstrated that age at diagnosis, which may incorporate other genetic and environmental factors, is more important than GAA length in predicting cardiomyopathy, scoliosis, and disease progression. © 2008 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Friedreich ataxia</term></item><item><term>genotype</term></item><item><term>phenotype</term></item><item><term>GAA expansion</term></item><item><term>medication</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-06-26">Received</change><change when="2008-07-01">Registration</change><change when="2008-10-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/4114A5D3C6DC7EF365712917777C0686C790C098/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="140"><doi origin="wiley" registered="yes">10.1002/mds.v23:14</doi><numberingGroup><numbering type="journalVolume" number="23">23</numbering><numbering type="journalIssue">14</numbering></numberingGroup><coverDate startDate="2008-10-30">30 October 2008</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="100" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22248</doi><idGroup><id type="unit" value="MDS22248"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2008 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-06-26"></event><event type="manuscriptRevised" date="2008-04-02"></event><event type="manuscriptAccepted" date="2008-07-01"></event><event type="publishedOnlineEarlyUnpaginated" date="2008-08-29"></event><event type="firstOnline" date="2008-08-29"></event><event type="publishedOnlineFinalForm" date="2008-10-27"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">2026</numbering><numbering type="pageLast">2032</numbering></numberingGroup><correspondenceTo>Neurogenetics Branch, NINDS, 35 Convent Drive, Building 35, Room 2A‐114, Bethesda, MD 20892‐3705</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22248.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="4"></count><count type="referenceTotal" number="24"></count><count type="wordTotal" number="5275"></count></countGroup><titleGroup><title type="main" xml:lang="en">Predictors of progression in patients with Friedreich ataxia<link href="#fn3"></link></title><title type="short" xml:lang="en">Predictors of Progression in FRDA Patients</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Alison</givenNames><familyName>La Pean</familyName><degrees>MS, CGC</degrees></personName><contactDetails><email>lapeana@ninds.nih.gov</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Neal</givenNames><familyName>Jeffries</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Chelsea</givenNames><familyName>Grow</familyName><degrees>DO</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af4"><personName><givenNames>Bernard</givenNames><familyName>Ravina</familyName><degrees>MD, MSCE</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Nicholas A.</givenNames><familyName>Di Prospero</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="US" type="organization"><unparsedAffiliation>Memorial Neurosciences, Gulfport, Mississippi, USA</unparsedAffiliation></affiliation><affiliation xml:id="af4" countryCode="US" type="organization"><unparsedAffiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Friedreich ataxia</keyword><keyword xml:id="kwd2">genotype</keyword><keyword xml:id="kwd3">phenotype</keyword><keyword xml:id="kwd4">GAA expansion</keyword><keyword xml:id="kwd5">medication</keyword></keywordGroup><fundingInfo><fundingAgency>National Institute of Neurological Disorders and Stroke</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Friedreich ataxia is an inherited, progressive, neurodegenerative disorder that is clinically heterogeneous. It is caused by a trinucleotide (GAA) repeat expansion resulting in frataxin loss and oxidative stress. We assessed clinical features including the development of cardiomyopathy and scoliosis and disease progression including loss of ambulation and interference with activities of daily living relative to the length of the GAA repeat, age of onset, and age of diagnosis in a retrospective cohort study of 61 genetically confirmed patients. The use of antioxidants such as vitamins, dietary supplements, and idebenone was also examined. Linear regression and Cox proportional hazard models assessed predictors to disease milestones. The shorter GAA allele accounted for part of the variability in the age of diagnosis (46%) and less in the age of onset (27%). Multivariate analysis demonstrated that age at diagnosis, which may incorporate other genetic and environmental factors, is more important than GAA length in predicting cardiomyopathy, scoliosis, and disease progression. © 2008 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn3"><p>Potential conflict of interest: None reported.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Predictors of progression in patients with Friedreich ataxia</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Predictors of Progression in FRDA Patients</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Predictors of progression in patients with Friedreich ataxia</title></titleInfo><name type="personal"><namePart type="given">Alison</namePart><namePart type="family">La Pean</namePart><namePart type="termsOfAddress">MS, CGC</namePart><affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</affiliation><description>Correspondence: Neurogenetics Branch, NINDS, 35 Convent Drive, Building 35, Room 2A‐114, Bethesda, MD 20892‐3705</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Neal</namePart><namePart type="family">Jeffries</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Office of the Clinical Director, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Chelsea</namePart><namePart type="family">Grow</namePart><namePart type="termsOfAddress">DO</namePart><affiliation>Memorial Neurosciences, Gulfport, Mississippi, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bernard</namePart><namePart type="family">Ravina</namePart><namePart type="termsOfAddress">MD, MSCE</namePart><affiliation>Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nicholas A.</namePart><namePart type="family">Di Prospero</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, NIH, Bethesda, Maryland, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2008-10-30</dateIssued><dateCaptured encoding="w3cdtf">2007-06-26</dateCaptured><dateValid encoding="w3cdtf">2008-07-01</dateValid><copyrightDate encoding="w3cdtf">2008</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">4</extent><extent unit="references">24</extent><extent unit="words">5275</extent></physicalDescription><abstract lang="en">Friedreich ataxia is an inherited, progressive, neurodegenerative disorder that is clinically heterogeneous. It is caused by a trinucleotide (GAA) repeat expansion resulting in frataxin loss and oxidative stress. We assessed clinical features including the development of cardiomyopathy and scoliosis and disease progression including loss of ambulation and interference with activities of daily living relative to the length of the GAA repeat, age of onset, and age of diagnosis in a retrospective cohort study of 61 genetically confirmed patients. The use of antioxidants such as vitamins, dietary supplements, and idebenone was also examined. Linear regression and Cox proportional hazard models assessed predictors to disease milestones. The shorter GAA allele accounted for part of the variability in the age of diagnosis (46%) and less in the age of onset (27%). Multivariate analysis demonstrated that age at diagnosis, which may incorporate other genetic and environmental factors, is more important than GAA length in predicting cardiomyopathy, scoliosis, and disease progression. © 2008 Movement Disorder Society</abstract><note type="content">*Potential conflict of interest: None reported.</note><note type="funding">National Institute of Neurological Disorders and Stroke</note><subject lang="en"><genre>Keywords</genre><topic>Friedreich ataxia</topic><topic>genotype</topic><topic>phenotype</topic><topic>GAA expansion</topic><topic>medication</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><detail type="issue"><caption>no.</caption><number>14</number></detail><extent unit="pages"><start>2026</start><end>2032</end><total>7</total></extent></part></relatedItem><identifier type="istex">4114A5D3C6DC7EF365712917777C0686C790C098</identifier><identifier type="DOI">10.1002/mds.22248</identifier><identifier type="ArticleID">MDS22248</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2008 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001845 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001845 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:4114A5D3C6DC7EF365712917777C0686C790C098
|texte= Predictors of progression in patients with Friedreich ataxia
}}
| This area was generated with Dilib version V0.6.23. |  |